Upload Avatar (500 x 500)
Guilling Wang
Life Science
China Medical University
Liaoning
Language: Chinese, English
Gene Signaling
Tumor
Cell Metabolism
Abnormalities
Therapy
Medicine
Engineering
Integration
Networks
Regulation
Areas of Focus
- Tumor-related gene signaling networks
- Cell metabolism abnormalities and tumors
- Integration of medicine and engineering in tumor therapy
Work Experience
- 2016-2018 - New Jersey Cancer Institute - Research on cell metabolism and lung cancer
- Current - China Medical University - Professor in Molecular Cell Biology
Academic Background & Achievements
- 2016-2018: Research at New Jersey Cancer Institute, USA
- Awarded 'Outstanding Young Backbone Teacher of Higher Education in Liaoning Province'
- Supervised students who received 'Outstanding Master's Thesis in Liaoning Province'
Publications
- MORC2 regulates C/EBPα-mediated cell differentiation via sumoylation., Guilling Wang, 2019
- MORC protein family-related signature within human disease and cancer., Guilling Wang, 2021
- Attachment of -tBu groups to aza-BODIPY core at 3,5-sites with ultra-large Stokes shift to enhance photothermal therapy through apoptosis mechanism., Guilling Wang, 2022
- Combination of niclosamide and current therapies to overcome resistance for cancer: New frontiers for an old drug., Guilling Wang, 2022
- Niclosamide as a Promising Therapeutic Player in Human Cancer and Other Diseases., Guilling Wang, 2022
- Synthesis of aza-BODIPYs with barrier-free rotation of the -tBu group at 3-site and enhancement of photothermal therapy by triggering cancer cell apoptosis., Guilling Wang, 2022
- Engineering J-aggregates for NIR-induced meso-CF3-BODIPY nanoparticles by activated apoptosis mechanism in photothermal therapy., Guilling Wang, 2023
- Construction of diene-extended meso-CF3-BODIPY for spectroscopic study and photothermal exploration., Guilling Wang, 2023
- Development of functional dye with redshifted absorption based on Knoevenagel condensation at 1-site in phenyl[b]-fused BODIPY., Guilling Wang, 2023
- Oncogenic MORC2 in Cancer Development and Beyond., Guilling Wang, 2023
- Aza-BODIPY with two efficacious fragments for NIR light-driven photothermal therapy by triggering cancer cell apoptosis., Guilling Wang, 2023
- Heavy-atom-free orthogonal configurative dye 1,7-di-anthra-aza-BODIPY for singlet oxygen generation., Guilling Wang, 2023
- YTHDF1 in Tumor Cell Metabolism: An Updated Review., Guilling Wang, 2023
- Unlocking the adenosine receptor mechanism of the tumour immune microenvironment., Guilling Wang, 2024
- tert-Butyl substituted aza-BODIPY-based bromides for phototherapy., Guilling Wang, 2024
Awards
- Liaoning Province Science and Technology Second Prize
- Liaoning Province Natural Science Academic Achievement Award Second Prize
